|  |  |  |  |
| --- | --- | --- | --- |
| **Section/Topic**  | **ItemNo**  | **Checklist item**  | **Reported on page No**  |
| **Title and abstract**  | 1a  | Identification as a randomised trial in the title | 1 |
|  | 1b | Structured summary of trial design, methods, results, and conclusions (for specific guidance see CONSORT for abstracts) | 2 |
| **Introduction** |  |  |  |
| Background and objectives  | 2a  | Scientific background and explanation of rationale | 4-5 |
|  | 2b  | Specific objectives or hypotheses | 5 |
| **Methods**  |  |  |  |
| Trial design  | 3a | Description of trial design (such as parallel, factorial) including allocation ratio | 5, 7 |
|  | 3b  | Important changes to methods after trial commencement (such as eligibility criteria), with reasons | 5-6 |
| Participants  | 4a  | Eligibility criteria for participants | 6-7 |
|  | 4b  | Settings and locations where the data were collected | 5-6 and published protocol (referenced in manuscript, 15) |
| Interventions  | 5 | The interventions for each group with sufficient details to allow replication, including how and when they were actually administered | 8-11 |
| Outcomes  | 6a | Completely defined pre-specified primary and secondary outcome measures, including how and when they were assessed  | 11-13. supplementary figure 1, Supplementary Table S3 |
|  | 6b | Any changes to trial outcomes after the trial commenced, with reason | NA |
| Sample size  | 7a | How sample size was determined | 13 |
|  | 7b | When applicable, explanation of any interim analyses and stopping guidelines  | NA |
| Randomisation:  |  |  |  |
| Sequence generation | 8a | Method used to generate the random allocation sequence | 7  |
|  | 8b | Type of randomisation; details of any restriction (such as blocking and block size)  | 8, 13 and reference to the trial protocol |
| Allocation concealment mechanism  | 9 | Mechanism used to implement the random allocation sequence (such as sequentially numbered containers), describing any steps taken to conceal the sequence until interventions were assigned  | In published protocol (15) |
| Implementation  | 10 | Who generated the random allocation sequence, who enrolled participants, and who assigned participants to interventions  | Page 8 and in published protocol (15) |
| Blinding  | 11a | If done, who was blinded after assignment to interventions (for example, participants, care providers, those assessing outcomes) and how | Page 8 and in published protocol (15) |
|  | 11b | If relevant, description of the similarity of interventions | 9, 11 |
| Statistical methods  | 12a | Statistical methods used to compare groups for primary and secondary outcomes  | 13-14 |
|  | 12b | Methods for additional analyses, such as subgroup analyses and adjusted analyses  | NA |
| **Results**  |  |  |  |
| Participant flow (a diagram is strongly recommended)  | 13a | For each group, the numbers of participants who were randomly assigned, received intended treatment, and were analysed for the primary outcome  | Figure S1  |
|  | 13b | For each group, losses and exclusions after randomisation, together with reasons  | Figure S1  |
| Recruitment | 14a | Dates defining the periods of recruitment and follow-up | Figure S1  |
|  | 14b | Why the trial ended or was stopped  | NA |
| Baseline data  | 15 | A table showing baseline demographic and clinical characteristics for each group | 15, 16 (table 2), Supplementary Table S5 |
| Numbers analysed | 16 | For each group, number of participants (denominator) included in each analysis and whether the analysis was by original assigned groups | Supplementary Table S5 |
| Outcomes and estimation  | 17a | For each primary and secondary outcome, results for each group, and the estimated effect size and its precision (such as 95% confidence interval) | Text: 16-18 ,20-23, Table 3, Supplementary Table S4, Supplementary Table S6, Supplementary Table S8,  |
|  | 17b | For binary outcomes, presentation of both absolute and relative effect sizes is recommended  | Supplementary Table S8 |
| Ancillary analyses  | 18 | Results of any other analyses performed, including subgroup analyses and adjusted analyses, distinguishing pre-specified from exploratory  |  |
| Harms  | 19 | All important harms or unintended effects in each group (for specific guidance see CONSORT for harms)  | NA |
| **Discussion**  |  |  |  |
| Limitations  | 20 | Trial limitations, addressing sources of potential bias, imprecision, and, if relevant, multiplicity of analyses | 26 |
| Generalisability  | 21 | Generalisability (external validity, applicability) of the trial findings | 26 |
| Interpretation  | 22 | Interpretation consistent with results, balancing benefits and harms, and considering other relevant evidence  | 23-28 |
| **Other information**  |  |  |  |
| Registration | 23 | Registration number and name of trial registry | 3, 14 |
| Protocol  | 24 | Where the full trial protocol can be accessed, if available | Reference 15 and uploaded in supporting information  |
| Funding  | 25 | Sources of funding and other support (such as supply of drugs), role of funders  | 4, 9, 14, 35 |